Is ABO blood group truly a risk factor for thrombosis and adverse outcomes?

Shan Zhou, Ian Welsby

Shan Zhou, Ian Welsby, Department of Anesthesiology, Duke University Medical Center 3094, Durham, NC 27710, United States
Shan Zhou, Department of Anesthesiology, Fuwai Cardiovascular Hospital, Chinese Academy of Medical Science, Peking Union Medical School, Beijing 100037, China

Author contributions: Zhou S and Welsby I contributed to this paper.

Correspondence to: Dr. Ian Welsby, Department of Anesthesiology, Duke University Medical Center 3094, 2301 Erwin Road, Durham, NC 27710, United States. ian.welsby@dm.duke.edu

Received: March 15, 2014 Revised: April 29, 2014 Accepted: July 12, 2014 Published online: September 26, 2014

Abstract

ABO blood type is one of the most readily available laboratory tests, and serves as a vital determinant in blood transfusion and organ transplantation. The ABO antigens are expressed not only on red blood cell membranes, determining the compatibility of transfusion, but also on the surface of other human cells, including epithelium, platelet and vascular endothelium, therefore extending the research into other involvements of cardiovascular disease and postoperative outcomes. ABO blood group has been recognized as a risk factor of venous thrombosis embolism since the 1960’s, effects now understood to be related to ABO dependent variations are procoagulant factor VIII (FVIII) and von Willebrand factor (vWF) levels. Levels of vWF, mostly genetically determined, are strongly associated with venous thromboembolism (VTE). It mediates platelet adhesion aggregation and stabilizes FVIII in plasma. Moreover, many studies have tried to identify the relationship between ABO blood types and ischemic heart disease. Unlike the clear and convincing associations between VTE and ABO blood type, the link between ABO blood type and ischemic heart disease is less consistent and may be confusing. Other than genetic factors, ischemic heart disease is strongly related to diet, race, lipid metabolism and economic status. In this review, we’ll summarize the data relating race and genetics, including ABO blood type, to VTE, ischemic heart disease and postoperative bleeding after cardiac surgery.

Key words: ABO blood group; Venous thrombosis; Ischemia disease; Cardiac surgery; Outcomes

Core tip: In this review, we updated the reports regarding the associations between ABO blood groups and venous thrombosis, ischemic heart disease as well as postoperative outcomes after cardiac surgery. ABO blood group is clearly associated with venous thromboembolism whereas critical review of the literature reveals a more controversial relationship with atherosclerosis, arterial thrombosis and postoperative outcomes.

INTRODUCTION

The ABO group of human red cell antigens was discovered by Karl Landsteiner in 1900. ABO antigens are carbohydrate molecules that are the major determinants of the compatibility of red cell transfusions. Naturally occurring, complement fixing IgM antibodies are formed against the A and B antigens in individuals that do not express them on their red cell surfaces and therefore recognize them as foreign antigens. Each individual inherits
two ABO alleles. The A and B alleles encode separate glycosyltransferase that add N-acetylgalactosamine and D-galactose of the “H” antigen (group O determinant), converting it into A and B antigens respectively. However, as the O allele does not express either A or B transferase enzymes, continued expression of the unaltered H antigen is the phenotypic marker of the O blood group[11]. The ABO antigens are expressed not only on red blood cell membranes, determining the compatibility of transfusion, but also on the surface of other human cells, including epithelium, platelet and vascular endothelium[2], therefore extending potential pathophysiology into other areas of cardiovascular disease and postoperative outcomes.

Expression of the different ABO phenotypes is partially dependent on racial origin as shown in Table 1, with Group O generally being the most common blood group[3, 8]. Blood groups are basically described by phenotypes, because historically blood groups are determined by commercial antibodies that recognize A and B antigens. By this detection method, both AO and AA genotypes (A^1^O', A^2^A') will be identified as group A, while BO and BB genotypes as group B. In this review, we updated the reports regarding the associations between ABO blood groups and venous thrombosis, ischemic heart disease as well as postoperative outcomes in terms of both ABO phenotype and genotype.

### ABO AND VON WILLEBRAND FACTOR

Von Willebrand factor (vWF) has two major biological forms and the high molecular weight vWF (HMW vWF) is hemostatically more active than the low molecular weight vWF (LMW vWF)[8]. HMW vWF mediates the interaction between platelets and damaged areas of the blood vessel wall, while LMW vWF acts as a specific carrier molecule for procoagulant factor VIII (FVIII), thereby localizing FVIII to the site of any vascular injury. Both are essential for normal hemostasis[9].

Plasma vWF levels are generally reported to be approximately 25% higher in non-O blood individuals[5]. Synthesized in endothelial cells and megakaryocytes, the HMW vWF, enters the plasma from platelet granules following platelet activation and degranulation at the site of tissue injury, or alternatively being stored in endothelial cell Weibel-Palade bodies, then secreted in response to thrombin, fibrin or histamine stimulation[20]. vWF molecule has three binding sites, platelet glycoprotein Ib binds to A1 domain, while collagen binds to A3 domain, forming the primary hemostatic clot[20]. The A2 domain binds to ADAMTS13 and is responsible for vWF cleavage (Figure 1).

Clinical observations that the severity of bleeding in mild von Willebrand’s disease was exaggerated for group O patients led to the recognition of an ABO dependent variation in vWF levels[11-13]. A formal linkage analysis showed the effect of ABO blood type on von Willebrand factor is a direct functional effect of the ABO locus, rather than linkage disequilibrium between the ABO locus and another unidentified VWF regulation locus[14]. vWF levels can also influence procoagulant FVIII levels since vWF is a carrier molecule that protects FVIII from proteolysis in plasma.

Moeller et al[15] compared vWF and FVIII levels in individuals of different ABO phenotype and found ascending order O < A < B < AB for vWF level and O < A < AB < B for FVIII level. This effect becomes more nuanced when considering the specific genotypes that result in ABO phenotypes, as illustrated in Table 2. Within A and B phenotypes, vWF concentrations in AA or BB are slightly higher than AO or BO[16] and A^1^ and B^1^ alleles are found to be associated with higher vWF and FVIII levels, while A^2^ is comparable to O allele[6, 11, 13, 17].

### MECHANISM FOR ABO RELATED VARIABILITY IN VWF LEVELS

There is no direct evidence demonstrating that the ABO locus is associated with vWF synthesis[8], therefore efforts to elucidate the association between ABO and vWF have focused on vWF metabolism and cleavage. ADAMTS13 cleavages HMW vWF to LMW vWF[15, 18, 19], thereby modulating the tendency of vWF to cause platelet aggregation and thrombus formulation[20]. The biological importance of this is exemplified by thrombotic thrombocytopenic purpura (TTP). In TTP, autoantibodies neutralize ADAMTS13 leading to diffuse microvascular thrombosis from the unregulated action of HMW vWF. This extreme example leads to a proposed mechanism for the ABO group related modulation of vWF levels and therefore tendency to thrombosis. While A, B and H antigens are more commonly known to be expressed on the cell surfaces of erythrocytes and various exocrine cells, they are also expressed on the vWF molecule. The

---

**Table 1** The incidence of ABO phenotypes in populations from different racial backgrounds

| Race    | Blood group phenotype | Blood group genotypes |
|---------|-----------------------|-----------------------|
| Caucasian | O` | O` rare | A^1^ | A^2^ | B | A'B | A^1^B | A^2^B |
| Asian    | 44% | 33%  | 10%  | 9%  | 3% | 1%  |
| African  | 43% | 27%  | 5%  | 25% | 5% | Rare |

Illustrations: Sub-group A2 expresses less A antigen on the red cell surface and has been referred to as “weak” A.

**Table 2** The association of ABO genotype with von Willebrand factor and factor VIII levels is presented with categorization by von Willebrand factor levels

| Genotype | Median value |
|----------|--------------|
| vWF      | FVIII        |
| Low      | O'O         | 69% | 75% |
| Medium   | A'O, A'O, BO| 89% | 96% |
| High     | AA, BB, A'B | 120%| 117%|
| Highest  | A'B         | 169%| 112%|

vWF: Von Willebrand factor; FVIII: Factor VIII.
Figure 1  Genetic and environmental factors that contribute to increased levels of von Willebrand factor and factor V and risk of thrombus formation. ADAMTS13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; AT3: Antithrombin III; DM: Diabetes mellitus; F II: Prothrombin gene mutation 20120A; F III: Factor V; FVL: Factor V leiden; LRP: Lipoprotein receptor-related protein; TSP-1: Thrombospondin-1; vWF: Von Willebrand factor.

location of the A, B and H antigens on the vWF molecule is thought to be close to the A2 domain binding site for ADAMTS13 and that A and B antigens reduce ADAMTS13 binding and, therefore, cleavage[8,23]. Some studies confirmed this hypothesis by providing evidence that the proteolytic effect of ADAMTS13 on vWF was significantly faster in O group (only H antigen expression) than in non-O groups with A and B antigen expression[22,24]. Factors other than ABO group can also modify vWF metabolism which may limit the direct association of ABO group with vWF levels and thrombosis, explaining some inconsistencies in the various studies we report. For example, thrombospondin-1 (TSP-1) has been reported to control vWF multimer size by both directly cleavage and indirectly, competing with ADAMTS13[24,25]. Thus, any genetic factors influence cleavage (ABO blood type, ADAMTS13 and TSP-1) and environmental risk factors that affect endothelial cell function, such as age, diabetes mellitus, hypertension, inflammatory and oral contraceptive drugs, all contribute to the complex risk factors leading to clinical thrombosis. This concept is illustrated in Figure 1.

The link between ABO blood group, H antigen expression and lower vWF levels has been well established above. How this translates into a clinically relevant risk of thromboembolism manifesting either as venous thromboembolism or coronary artery thrombosis is discussed in detail below.

VENOUS THROMBOEMBOLISM

Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism and is a serious medical condition with a historical mortality rate of 10% and 15% respectively[26]. ABO blood group has been recognized as a risk factor since the 1960s, effects now understood to be related to ABO dependent variations are procoagulant FVIII and vWF levels. Levels of vWF, mostly genetically determined, are strongly associated with VTE. It mediates platelet adhesion aggregation and stabilizes FVIII in plasma. In a healthy state, twin studies showed 75% of variance in plasma vWF levels result from genetic determinants[27], 30% of which are associated with ABO blood type[28]. Other non-genetic factors, such as aging, diabetes, free radical formation and inflammation, may have a more important role during acute illnesses or during the perioperative period[29]. As shown in Figure 1, environmental causes of endothelial dysfunction can greatly affect vWF levels.

Numerous studies have reported that individuals with non-O blood types had a higher risk of VTE compared to their O counterparts[30-34]. According to Wiggins, compared to O’O’ group, AB diploptype category has the highest VTE rate, followed by B allele and A1 allele[18]. Other rare genotypes like A1, A2, A’, B’, were less amenable to statistically meaningful comparison in this study. These observations were supported by genotype association studies that showed H-antigen rich genotypes (O’O’, O’O’, O’A1) have a lower incidence of VTE than H-antigen poor genotypes (A’B, O’A1, O1B)[17,35,36], establishing ABO blood type as an important risk factor for VTE[37].

In Figure 1, various genetic and environmental factors affecting vWF levels are presented. What’s more, FVIII, circulating bound to vWF, also plays a crucial and independent role in the propagation phase of coagulation
activation[6]. Since vWF is the plasma co-activator of FVIII, ABO blood type, by altering vWF levels, also exerts an effect on FVIII levels. Tirado et al[34] demonstrated that genetic factors explain 40% of the variance of FVIII levels; other studies further identified a quantitative trait locus and the ABO locus as two major genetic factors underlying the variability of FVIII levels[14,38]. Unconnected to ABO group, lipoprotein receptor-related protein has also been identified to be associated with degradation of FVIII, another consideration when evaluating variance in FVIII levels[39]. In summary, while ABO blood type and vWF levels are two important factors commonly known to modulate FVIII plasma level, the biology determining FVIII levels is a complex interaction of genetic and environmental factors as illustrated in Figure 1.

However, FVIII may have some effect independent of vWF. Some studies demonstrated that a high FVIII level is persistent beyond the acute phase state[40,41], representing a potential risk factor for delayed or recurrent thrombosis. In addition, Moran et al[17] described a residual statistical effect of ABO blood group on FVIII levels after adjustment for vWF levels, postulating that FVIII is an independent VTE risk factor[20,14]. Additionally, FVIII was reported to be associated with recurrent disease[14], consistent with reports that non-O carriers had a higher incidence of VTE recurrence than O carriers[42,43].

**ISCHEMIC HEART DISEASE**

Unlike the clear and convincing associations between VTE and ABO blood type, the link between ABO blood type and ischemic heart disease is less consistent and may be confusing. In part this can be due to the inclusion of different end-points that may represent different disease processes, such as angina/atherosclerosis (less likely ABO/vWF related) or myocardial infarction (MI)/coronary thrombosis (more likely ABO/vWF related). The pathogenesis of coronary artery disease (CAD) involves the progression of an atherosclerotic disease process, whereas MI (or acute coronary syndrome) results from a platelet rich thrombus forming on abnormal endothelium diseased by the atherosclerotic process. Platelet rich thrombi (MI) are reliant on primary hemostasis, whereas the mechanism linking ABO group to CAD is less obvious. However, it is important to evaluate ABO group as a risk factor for both these devastating conditions: CAD and MI.

Many studies show that non-O group have higher incidence of ischemic heart disease (Table 3). The Framingham Heart study, and others, suggested A blood type has increased risk of CAD[44-46] and MI[47]; more specifically, A blood group seems to be related to early CAD detection[47,48] and predominates in patients with MI[49]. Other studies noted groups B[50,51] or AB[52] have higher incidence of CAD. Conversely, Mitchell[53] reported that towns with a higher prevalence of group O have higher rates of cardiovascular mortality and an Indian study with moderate sample size also showed O blood group is more frequent in CAD and increased the risk of CAD[44]. Further studies do not identify any association between blood type and CAD[53,54]. Based on these inconsistent results and relative small sample sizes. He[55] conducted a meta-analysis of two large, prospective studies consisting of 89501 participants, and found the highest risk of CAD was observed in blood group AB, followed by group B, A and O. This is consistent with what we know about ABO related vWF/FVIII levels with the highest in group AB, followed by group B, A and O. According to

### Table 3 Outline of the main studies describing the association of ABO blood type and manifestations of atherosclerotic heart disease

| Ref.         | Population               | Sample size | Outcome(s)                  | Findings                               |
|--------------|--------------------------|-------------|------------------------------|----------------------------------------|
| Garrison et al[40] | United States          | 7662        | “Cardiovascular disease”     | O showed the lowest incidence          |
| Whincup et al[41] | United Kingdom (men only) | 225 MI vs 802 controls | MI | Blood group A was associated with MI |
| Rosenberg et al[42] | United States (young women) | 136 CAD vs 129 without CAD | CAD and MI | Group A was associated with increased risk of CAD (OR = 2.61, CI: 1.11-6.14) and MI (OR = 3.53, CI: 1.21-10.29) |
| Lee et al[43] | Taiwan (young patients)  | 476 MI vs 203 healthy control | MI | ABO blood type is not associated with development of MI |
| Sari et al[44] | Turkey                  | 4901        | MI and CAD                  | Group non-O is associated with increased mortality in patients with CAD, groups A and B prevail in MI |
| Carpeggiani et al[45] | Italy                |             | “Cardiovascular disease”     | B allele carriers had higher MI (OR = 2.7, CI: 1.1-6.8) |
| Nydegger et al[46] | Lithuania              | 177 patients vs 89 control | MI | B blood group can be related with CAD in women |
| Staknisitis et al[47] | United Kingdom     | 441         | CAD and MI                  | Incidence was significantly higher in blood group AB |
| Mitchell et al[48] | United Kingdom         | 1393 men with 178 IHDS | CAD | Towns with higher prevalence of group O have higher rate of cardiovascular mortality |
| Biswas et al[49] | India                   | 250 CAD vs 250 controls | CAD | Group O increases the risk of CAD |
| Amirzadeeghan et al[50] | Iran                  | 2076 patients | CAD | No correlation |
| Biancari et al[51] | Finland                 | 1152 CABG patients | MI | No correlation |
| He et al[52]   | United States          | 89501       | Coronary heart disease      | AB group has highest CAD risk, followed by groups B, A and O |

CAD: Coronary artery disease; MI: Myocardial infarction.
this meta-analysis, non-O group has an 11% increased risk of CAD, an association not altered by adjusting for other co-morbidities. There was, however, no difference in survival and, paradoxically, a trend towards increased mortality and/or non-fatal myocardial infarction in O blood type patients.

The relationship between ABO genotype and CAD has also been investigated. Wiggins et al.\(^1\) reported an 18% increased MI risk associated with A\(^1\) allele carriers compared to O\(^1\) homozygotes, but no other associations were found between B or AB alleles and MI, possibly due to underpowering as B and AB groups are relatively rare. An investigation of postmenopausal women suggested A or B allele carriers almost had two-fold incidence of acute ischemic heart disease compared to OG\(^1\). Similarly, Nydegger et al.\(^2\) showed a three-fold risk of MI with the presence of B allele (genotype AB, BB or BO) compared to non B allele (genotype OO, AO, AA) in a smaller case-control study. Another study\(^3\) with angiography showed O\(^1\) allele carriers had a 39% decreased risk of MI compared to non O\(^1\). More obviously, von Beckerath et al.\(^4\) found a dose-dependent effect with carriage of one or two O\(^1\) alleles being associated with decreased risks of acute MI. However, a recently published study by Reilly et al.\(^5\) argued that ABO locus did not predict MI in patients with known CAD, but was strongly associated with the presence of CAD in two large genome wide association studies. Whether ABO alleles are associated with the development of MI or only the presence of CAD is not yet clearly defined. It is much easier to investigate the risk factors for CAD prevalence in a cross-sectional study than to evaluate the incidence of MI with a prospective design, as the latter requires a stable cohort with years of detailed follow-up. Currently, the association of MI and ABO blood group has only been well reported in survivors of MI events. This introduces bias, as patients may suffer an asymptomatic MI, not present at hospital, or die before diagnosis.

There are some mechanisms proposed to explain the association between ABO blood type and CAD, but a unifying theory remains elusive. Along with fibrinogen, vWF may play a role in the progression of atherosclerosis by promoting platelet aggregation and adhesion\(^6\). On the other hand, blood group A has been noted to have higher levels of cholesterol and low density lipoprotein\(^6\), which may partly explain the association with an increased risk of CAD. Additionally, the ABO locus was recently reported to be associated with CAD related inflammatory makers, including intercellular adhesion molecule-1, soluble P-selectin\(^7\), soluble E selectin\(^8\) and tumor necrosis factor-\(\alpha\)\(^9\). Still, the interactions among genetic factors (known genes increasing susceptibility to CAD and the ABO locus) and environmental factors conferring risk for CAD and MI are complicated. It is unclear which ABO phenotypes or genotypes increase CAD and/or MI risk; this risk may differ for the incidence of CAD or MI and survival following MI.

**CARDIAC SURGERY**

Our group performed a retrospective study to evaluate the relationship between ABO blood types and postoperative bleeding in cardiac surgical patients. This was based on the hypothesis that lower circulating vWF levels seen with group O may reduce primary hemostasis resulting in increased postoperative bleeding. While group O did have impaired baseline measures of primary hemostasis and required less heparin and protamine for perioperative anticoagulation, the result showed no difference of postoperative bleeding between different blood groups\(^10\).

Limitations of such perioperative studies are the lack of intermediate, mechanistic measures of factor levels and the confounding effects of the acute phase response that may drown out an ABO effect. Also, the classification by phenotype is limited. For example, the A\(^\alpha\)O genotype with low vWF levels and the A\(^\alpha\)A genotype with high vWF levels are both classified as group A. In addition, the statistically convenient categorization into O and non-O phenotype is flawed for the same reason, blurring comparison between H antigen rich and H antigen poor genotypes that have been shown to drive the association between ABO blood type and outcome. As an alternative approach, we have preliminary results suggesting that the AB phenotype (no H antigen) requires less perioperative transfusion than non-AB phenotypes and this is associated with better postoperative survival for the rare AB group. These findings require confirmation with prospective study.

**CONCLUSION**

In summary, ABO blood group is an important determinant of vWF and F\(\text{VIII}\) levels which in turn confer a clear risk of increased VTE with the higher levels seen in the non-O blood types. The associations are far less clear for CAD and MI but a similar pattern emerges with most studies finding group O to be at lower risk. In terms of perioperative bleeding and transfusion, a possible reciprocal for thrombosis, further work needs to be done to determine a consistent ABO effect.

**REFERENCES**

1. Lowe JB. The blood group-specific human glycosyltransferases. Baillieres Clin Haematol 1993; 6: 465-492 [PMID: 8049335 DOI: 10.1016/S0950-3536(05)80155-6]
2. Franchini M, Rossi C, Mengoli C, Frattini F, Crestani S, Giacomini L, Luppi M, Bonfanti C. ABO blood group and risk of coronary artery disease. J Thromb Thrombolysis 2013; 36: 286-287 [PMID: 23096597 DOI: 10.1007/s11239-012-0836-1]
3. Fang C, Cohen HW, Billett HH. Race, ABO blood group, and venous thromboembolism risk: not black and white. Transfusion 2013; 53: 187-192 [PMID: 22536799 DOI: 10.1111/j.1537-2995.2012.05665.x]
4. Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease. Hamostaseologie 2009; 29: 32-38 [PMID: 19151843]
5. Dentali F, Sironi AP, Ageno W, Crestani S, Franchini M.
ABO blood group and vascular disease: an update. Semin Thromb Hemost 2014; 40: 49-59 [PMID: 24381150 DOI: 10.1055/s-0033-1364640].

19 Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977; 252: 5538-5546 [PMID: 301377].

20 Welshy JJ, Jones R, Pylman J, Mark JB, Brudney CS, Phillips-Bute B, Mathew JP, Campbell ML, Stafford-Smith M. ABO blood group and bleeding after coronary artery bypass graft surgery. Blood Coagul Fibrinolysis 2007; 18: 781-785 [PMID: 17982320 DOI: 10.1097/MBC.0b013e32821029c4].

21 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55 [PMID: 16543961].

22 Paiva SG, Sabino AP, Carvalho MG, Ribeiro DD, Gomes KB, Santos MS, Oliveira LS, Lages GG, Dusse LM, Fernandes AP. Polymorphisms in exons 6 and 7 of the ABO locus and their association with venous thrombosis in young Brazilian patients. Blood Coagul Fibrinolysis 2009; 20: 122-128 [PMID: 19786939 DOI: 10.1016/j.bcbf.2008-12-4856].

23 Bowen D. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40 [PMID: 12871537 DOI: 10.1111/j.1538-7836.2003.00007.x].

24 Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, Vervynken L, Lawler J, Hoyalets MF. Thrombopsonind-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood 2006; 107: 955-964 [PMID: 16204378 DOI: 10.1182/blood-2004-12-4856].

25 Bonnefoy A, Hoyalets MF. Thrombopsonind-1 in von Willebrand factor carr. Drug Targets 2008; 9: 822-832 [PMID: 18855616 DOI: 10.2174/138945008785909329].

26 Trégouët DA, Heath S, Naur B, Iouriandreani C, Schved JP, Pernod G, Galan P, Drouet L, Zelenika D, Juan-Vague I, Alessi MC, Tietl L, Lathrop M, Emmerich J, Morange PE. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009; 113: 5298-5303 [PMID: 19279955 DOI: 10.1182/blood-2008-11-190389].

27 de Lange M, Snieder H, Ariëns RA, Spector TD, Grant PG. The genetics of haemostasis: a twin study. Lancet 2001; 357: 101-105 [PMID: 11197396 DOI: 10.1016/s0140-6736(00)03541-8].

28 Orstavik KH, Magnus P, Reissner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89-101 [PMID: 3919573].

29 Ohira T, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Zakai NA, Rosamond WD, Folsom AR. ABO blood group, other risk factors and incidence of venous thromboembolism: the longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455-1461 [PMID: 17425663 DOI: 10.1111/j.1538-7836.2007.02579.x].

30 Jack H, Stone D, Westerholm B, Inman WH, Vessey MP, Shapiro S, Lewis GP, Worcestar J. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-542 [PMID: 4179835 DOI: 10.1016/s0140-6736(09)99155-2].

31 Robinson WM, Roisenberg I. Venous thromboembolism and ABO blood groups in a Brazilian population. Hum Genet 1980; 55: 129-131 [PMID: 7450749 DOI: 10.1007/BF00329140].

32 Wautrecht JC, Galle C, Motte S, Dereume JP, Daramaix M. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998; 79: 688-689 [PMID: 9723699].

33 Larsen TB, Johnsen SP, Gislum M, Møller CA, Larsen H, Sørensen HT. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J Thromb Haemost 2005; 3: 300-304 [PMID: 15670036 DOI: 10.1111/j.1538-7836.2005.01195.x].

34 Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Valvè C, Borrell M, Urrutia T, Fontcabreta J. The ABO blood
group genotype and phenotype of factor VIII levels as independent risk factors for venous thromboembolism. *Thromb Haemost* 2005; 93: 468-474 [PMID: 15735796 DOI: 10.1267/tho0503468]

35 Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotypes with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. *Br J Haematol* 2005; 128: 100-107 [PMID: 15606555 DOI: 10.1111/j.1365-2410.2004.05249.x]

36 Buil A, Trégouët DA, Souto JC, Saut N, Germain M, Rotival M, Tretel C, Lambin F, Lathrop M, Zeller T, Alessi MC, Rodrigo de Cordoba S, Minzel T, Wild P, Fontcuberta J, Gagnon F, Emmertich J, Almasy L, Blankenberg S, Soria JM, Morange PE. C4BFP/C4BA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. *Blood* 2010; 115: 4644-4650 [PMID: 20212171 DOI: 10.1182/blood-2010-01-263088]

37 Sode BF, Allin KH, Dahl M, Gynelberg F, Nordestgaard BG. Risk of venous thromboembolism and blood group O association with factor V Leiden and prothrombin mutations and blood type. *CMAJ* 2013; 185: E229-E237 [PMID: 23382263 DOI: 10.1503/cmaj.121636]

38 Soria JM, Almasy L, Souto JC, Buil A, Martinez-Sanchez E, Mateo J, Borrell M, Stone WH, Lathrop M, Fontcuberta J, Blangero J. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. *Blood* 2003; 101: 163-167 [PMID: 12393556 DOI: 10.1182/blood-2002-06-1792]

39 Schwarz HP, Lenting PJ, Binder B, Mihaly J, Denis C, Dorner F, Turecek PL. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. *Blood* 2000; 95: 1703-1708 [PMID: 10868827]

40 O'Donnell J, Tuddenham EG, Manning R, Kembell-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. *Thromb Haemost* 1997; 77: 825-828 [PMID: 9184386]

41 Oger E, Lacut K, Van Dreden P, Bressolette L, Abgrall JF, Blouch MT, Scarabin PY, Mottier D. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. *Haematologica* 2003; 88: 465-469 [PMID: 12861975]

42 Vormittag R, Bencur P, Ay C, Tengler T, Vukovich T, Quehenberger P, Mannhalter C, Fabinger I. Low-density lipoprotein receptor-related protein 1 polymorphism 663 C & gt; T affects clotting factor VIII activity and increases the risk of venous thromboembolism. *J Thromb Haemost* 2007; 5: 497-502 [PMID: 17155964 DOI: 10.1111/j.1538-7836.2006.02337.x]

43 Gándara E, Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon L, Le Gal G, Polymoss S, Crowther M, Carrier M, Langlois N, Kovacs J, Little Ma J, Carson N, Ramsay T, Rodger MA. Non-OO blood type influences the risk of reocclusion of postmenopausal women under 50 years of age. *JAMA* 1983; 250: 2801-2806 [PMID: 6644958 DOI: 10.1001/jama.1983.03340200035025]

44 Lee HF, Lin YC, Lin CP, Wang CL, Chang CJ, Hsu LA. Association of blood group A with coronary artery disease in young adults in Taiwan. *Intern Med* 2012; 51: 1815-1820 [PMID: 22921000 DOI: 10.2169/internalmedicine.51.7173]

45 Rosenberg LM, Miller DR, Kaufman DW, Helmirch SP, Van de Carr S, Stolrey FD, Shaprio S. Myocardial infarction in women under 50 years of age. *JAMA* 1983; 250: 2801-2806 [PMID: 6644958 DOI: 10.1001/jama.1983.03340200035025]
Zhou S et al. ABO blood group for thrombosis and adverse outcomes

10.1016/s0140-6736(10)61996-4

61 George VT, Elston RC, Amos CI, Ward LJ, Berenson GS. Association between polymorphic blood markers and risk factors for cardiovascular disease in a large pedigree. Genet Epidemiol 1987; 4: 267-275 [PMID: 3478281 DOI: 10.1002/gepi.1370040405]

62 Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, Nambi V, Bretler M, Smith NL, Peters A, Lu C, Tracy RP, Aleksic N, Heeriga J, Keaney JF, Rice K, Lip GY, Vasan RS, Glazer NL, Larson MG, Uitterlinden AG, Yamamoto J, Durda P, Haritunians T, Psaty BM, Boerwinkle E, Hofman A, Koenig W, Jenny NS, Witteman JC, Ballantyne C, Benjamin EJ. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010; 19: 1863-1872 [PMID: 20167578 DOI: 10.1093/hmg/ddq061]

63 Qi L, Cornelis MC, Kraft P, Jensen M, van Dam RM, Sun Q, Girman CJ, Laurie CC, Mirel DB, Hunter DJ, Rimm E, Hu FB. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 2010; 19: 1856-1862 [PMID: 20147318 DOI: 10.1093/hmg/ddq057]

P- Reviewer: Redondo PC, Sabate M S- Editor: Song XX
L- Editor: A E- Editor: Liu SQ

www.wjgnet.com
